http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104188996-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ad888b44e677de28bb75d0d700a00275 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2014-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1651cea1cfbceb881e5fb856d26619b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f384d191e3b139c58c8eb3e2ce01248 |
| publicationDate | 2014-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104188996-A |
| titleOfInvention | Application of ardipusilloside I in preparing antitumor drugs |
| abstract | The invention discloses application of ardipusilloside I in preparing antitumor drugs. The antitumor effect of the ardipusilloside I is observed through in vitro inhibition assay carried out on in vitro tumor cells and the observation result shows that ardipusilloside I has a certain inhibition effect on ascitic type S180, liver cancer, U937, U14 and Lewis melanoma and has an obvious antitumor activity; in addition, ardipusilloside I hardly causes toxic or side effects. Ardipusilloside I and pharmaceutically acceptable accessories are prepared into antitumor drugs, and the antitumor drugs can be in any dosage form of injection, capsule, tablet, granules, pills, mixture and oral liquid. |
| priorityDate | 2014-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.